NewAmsterdam Pharma Company N.V. Payments to Acquire Debt Securities, Available-for-sale
NewAmsterdam Pharma Company N.V. (NAMS) reported Payments to Acquire Debt Securities, Available-for-sale of $193.34 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2025-08-06
- NewAmsterdam Pharma Company N.V. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $183.71M.
- NewAmsterdam Pharma Company N.V. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $9.63M.
- NewAmsterdam Pharma Company N.V. payments to acquire debt securities, available-for-sale for fiscal 2024 was $62.18M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2025-06-30 | $183.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $193.34M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $9.63M 10-Q · filed 2025-05-08 | ||
| 2024-12-31 | $62.18M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |